Vitamin D attenuates cardiac hypertrophy in rats via mRNA regulation of IL- 6 and its receptor

Author:

Nikkholgh Ahad1,Tavakoli Fatemeh1,Alborzi Nasrin1,Araste Fatemeh1

Affiliation:

1. Shahid Sadoughi University of Medical Sciences and Health Services

Abstract

Abstract Background: Interleukin-6 (IL-6), a pro-inflammatory cytokine, plays an important role in the pathogenesis of myocardial hypertrophy. By integrating its membrane receptor complex (gp-80), IL-6 activates the signal guidance components (gp-130) and activates the hypertrophic signaling pathways. There is some evidence that 1, 25 dihydroxyvitamin D exerts anti-hypertrophic effects, but the cellular and molecular mechanisms are not fully understood. The aim of this study was to evaluate the effect of calcitriol on the level of IL-6 and its receptor components in hypertrophied rat heart. Methods: Male rats were divided into control, hypertrophy, vitamin D+hypertrophy, and propylene glycol+hypertrophy groups. The groups receiving vitamin D and propylene glycol were treated two weeks before induction of hypertrophy and two weeks after hypertrophy. Myocardial hypertrophy was induced by abdominal aortic stenosis. Mean arterial blood pressure was measured by cannulation of the left carotid artery and expression of genes was determined by RT-PCR. Results: Blood pressure and heart to body weight ratio increased in hypertrophic groups compared to the control group (P<0. 01), but vitamin D administration decreased these parameters (P<0.05). Abdominal aortic stenosis increased IL-6 expression levels (P<0.001) and Vitamin-D decreased IL-6 mRNA levels (P<0.01). The expression of gp-80 in the hypertrophic group increased compared to the control group (P˂0.05) but vitamin D did not affect the expression of receptor subunits genes. Conclusions: The data from this study suggest a possible mechanism for the anti-hypertrophic effects of vitamin D through the regulation of inflammatory responses during hypertrophy. Thus, vitamin D can reduce IL-6 expression levels, thereby reducing hypertrophy.

Publisher

Research Square Platform LLC

Reference25 articles.

1. Global burden of cardiovascular diseases and risk factors, 1990–2019: update from the GBD 2019 study;Roth GA;J Am Coll Cardiol,2020

2. Liu Y, Chen X, Zhang H-G. Cardiac Hypertrophy: From Compensation to Decompensation and Pharmacological Interventions. Vol. 12: Frontiers Media SA; 2021. p. 665936.

3. Pathological vs. physiological cardiac hypertrophy;Kavazis AN;J Physiol,2015

4. Hypertrophy of the heart: a new therapeutic target?;Frey N;Circulation,2004

5. Molecular distinction between physiological and pathological cardiac hypertrophy: experimental findings and therapeutic strategies;Bernardo BC;Pharmacol Ther,2010

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3